{"Clinical Trial ID": "NCT01806259", "Intervention": ["INTERVENTION 1:", "- Ketorolac 30 mg", "\u2022 An active medicine to compare with a placebo", "- Ketorolac 30 mg IV", "INTERVENTION 2:", "- NaCl 0.9% 3mL", "- Ketorolac 30 mg IV"], "Eligibility": ["Incorporation criteria:", "Learn more Age of consent: 18-85 years Weight: 50-100 kg Neutrophils / Lymphocytes ratio >4 and/or \"negative triple\" histological state and/or positive lymph nodes", "- Exclusion criteria:", "* Previous cancer (percentage of basal cell skin cancer and cervical cancer in situ) Nonconformity or refusal of protocol Positive pregnancy test Mothers of childbearing or breast-feeding age Contraindication of NSAID intake within 5 days prior to randomization NSAID intended use within 30 days following randomization Non curative surgery (T4 or M1 tumour classification)"], "Results": ["Performance measures:", "- Survivors without recurrence", "2 years for primary analysis + 3 additional years for secondary analysis (From date of randomization to date of first documented progression or date of death of any cause, whichever occurs first, estimated up to 5 years)", "Time limit: 5 years", "Results 1:", "Title of arm/group: Ketorolac 30 mg", "Description of the arm/group: active medicine to compare with placebo", "- Ketorolac 30 mg IV", "Total number of participants analysed: 96", "Type of measure: Number of participants", "Unit of measure: Participants 80 83.3%", "Results 2:", "Title of arm/group: NaCl 0.9% 3mL", "Description of the arm/group: Ketorolac 30 mg IV", "Total number of participants analysed: 107", "Type of measure: Number of participants", "Unit of measure: Participants 96 89.7%"], "Adverse Events": ["Undesirable Events 1:", "Total: 8/96 (8.33 per cent)", "Hematoma requiring surgery 1/96 (1.04%)", "Any type (not related to bleeding) 7/96 (7.29%)", "Adverse Events 2:", "Total: 7/107 (6.54 per cent)", "Hematoma requiring surgery 0/107 (0.00 %)", "Any type (not related to bleeding) 7/107 (6.54 per cent)"]}